Search clinical trials for: ELLIPTA

Total 72 results

Innovative Medical

Completed

Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial

Astigmatism | Cataracts

United States
University Hospital, Bordeaux

Withdrawn

Description of the Ability to Learn How to Handle Inhaler Devices in Asthma (AUDIT)

Asthma

France
Bispebjerg Hospital
Rigshospitalet, Denmark

Completed

Urine Concentrations of Vilanterol After Inhaled Administration of Vilanterol/Fluticasone Furoate

Pharmacokinetics

Denmark
GlaxoSmithKline

Completed

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma

Asthma

United States, Argentina, Germany, Korea, Republic of, Romania, Russian Federation, Spain, Netherlands, Mexico, Brazil, Chile, Czechia
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of QVA149 in COPD Patients

Chronic Obstructive Pulmonary Disease

United States
Hallym University Kangnam Sacred Heart Hospital

Recruiting

Combined Intense Pulsed Light (IPL) With Fractional Erbium:YAG Laser Ablation in Scar Prevention

Intense Pulsed Light | Erbium-yttrium Aluminum Garnet Laser | Scar Prevention

Korea, Republic of
GlaxoSmithKline

Completed

Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)

Asthma

United States, Canada
Boehringer Ingelheim

Completed

A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol

Pulmonary Disease, Chronic Obstructive

United States
Pulmonary Research Institute of Southeast Michigan
GlaxoSmithKline

Completed

Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD

COPD

United States
University of Dundee
Boehringer Ingelheim; NHS Tayside

Completed

INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol (INCOGNITO)

Chronic Obstructive Pulmonary Disease

United Kingdom
Mundipharma Research Limited

Completed

A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma

Asthma

United Kingdom, Sweden, Australia, New Zealand, Slovakia
GlaxoSmithKline

Completed

Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects

Asthma

United Kingdom, Germany
Boehringer Ingelheim

Completed

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
Nguyen Thi Trieu, MD

Approved for marketing

Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B (HBV)

CHRONIC HEPATITIS B

Vietnam
GlaxoSmithKline

Withdrawn

Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma

Asthma
GlaxoSmithKline

Withdrawn

A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Canada, Germany
GlaxoSmithKline
Parexel

Completed

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Poland, United States, Russian Federation
GlaxoSmithKline

Completed

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Czechia
GlaxoSmithKline

Completed

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, United States, Netherlands, Czechia
The Cleveland Clinic

Enrolling by invitation

Migraine Medication Effects on Urinary Symptoms

Overactive Bladder | Migraine | Migraine Disorders | Overactive Detrusor | Interstitial Cystitis | Overactive Bladder Syndrome | Bladder Pain Syndrome

United States
Fundacio Privada Mon Clinic Barcelona
GlaxoSmithKline

Recruiting

ANTES B+ Clinical Trial (ANTES B+)

Chronic Obstructive Pulmonary Disease

Spain
GlaxoSmithKline

Completed

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

Asthma

Australia, United States, Argentina, Canada, Germany, Japan, Korea, Republic of, Romania, Russian Federation, Spain, South Africa, Netherlands, Poland, Italy, United Kingdom

3

Subscribe